Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare pulmonary disease characterised by the proliferation of smooth muscle-like cells (LAM cells), and an abundance of lymphatic vessels in LAM lesions. Studies reported that vascular endothelial growth factor-D (VEGF-D) secreted by LAM cells contributes to LAM-associated lymphangiogenesis, however, the precise mechanisms of lymphangiogenesis and characteristics of lymphatic endothelial cells (LECs) in LAM lesions have not yet been elucidated. In this study, human primary-cultured LECs were obtained both from LAM-affected lung tissues (LAM-LECs) and normal lung tissues (control LECs) using fluorescence-activated cell sorting (FACS). We found that LAM-LECs had significantly higher ability of proliferation and migration compared to control LECs. VEGF-D significantly promoted migration of LECs but not proliferation of LECs in vitro. cDNA microarray and FACS analysis revealed the expression of vascular endothelial growth factor receptor (VEGFR)-3 and integrin alpha 9 were elevated in LAM-LECs. Inhibition of VEGFR-3 suppressed proliferation and migration of LECs, and blockade of integrin alpha 9 reduced VEGF-D-induced migration of LECs. Our data uncovered the distinct features of LAM-associated LECs, increased proliferation and migration, which may be due to higher expression of VEGFR-3 and integrin alpha 9. Furthermore, we also found VEGF-D/VEGFR-3 and VEGF-D/ integrin alpha 9 signaling play an important role in LAM-associated lymphangiogenesis.

Automated summary

LAM-LECs exhibited higher proliferation and migration abilities compared to control LECs, potentially due to elevated expression of VEGFR-3 and integrin alpha 9. VEGF-D signaling through VEGFR-3 and integrin alpha 9 plays a crucial role in LAM-associated lymphangiogenesis.